nach oben

Erschienen in:

01.11.2015 | Original article

Association between high-sensitivity troponin T, left ventricular hypertrophy, and myocardial performance index

verfasst von: Onur Kaypakli, MD, Mustafa Gür, MD, Mehmet Yavuz Gözükara, MD, Hakan Uçar, MD, Ali Kivrak, MD, Taner Şeker, MD, Durmuş Yildiray Şahin, MD, Zafer Elbasan, MD, Caner Türkoğlu, MD, Murat Çayli, MD

Erschienen in: Herz | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

The prognostic importance of high-sensitivity cardiac troponin T (hs-cTnT) has recently been reported in patients with heart failure. The myocardial performance index (MPI), which combines parameters of both systolic and diastolic ventricular function, provides a better marker of left ventricular dysfunction in hypertensive patients with preserved left ventricular ejection fraction (LVEF).

Aim

We aimed to investigate the relationship between hs-cTnT and tissue Doppler-derived MPI in newly diagnosed hypertensive patients with preserved LVEF.

Methods

We studied 306 patients with newly diagnosed hypertension. The patients were divided into two groups according to their median MPI values: MPI_lo and MPI_high groups. The MPI was calculated from the pulsed-wave Doppler recordings. Left ventricular mass index (LVMI) was determined according to the Devereux formula. hs-cTnT, uric acid, and high-sensitivity C-reactive protein (hs-CRP) levels were measured in all patients.

Results

Hs-cTnT, hs-CRP, and uric acid levels were higher in the MPI_high group compared with the MPI_low group (p < 0.05, for all). The LVMI values in the MPI_high group were higher than in the MPI_low group (p < 0.05). MPI was independently associated with age, uric acid, hs-cTnT, and LVMI in multivariate analysis. Multivariate logistic regression analysis showed that MPI and LVMI were independent predictors of high hs-cTnT level in newly diagnosed hypertensive patients with preserved LVEF.

Conclusion

Hs-cTnT was independently associated with LV dysfunction and LV hypertrophy assessed with MPI in newly diagnosed hypertensive patients.

Kono M, Kisanuki A, Takasaki K et al (2009) Left ventricular systolic function is abnormal in diastolic heart failure: re-assessment of systolic function using cardiac time interval analysis. J Cardiol 53:437–446CrossRefPubMed

Yip G, Wang M, Zhang Y et al (2002) Left ventricular long axis function in diastolic heart failure is reduced in both diastole and systole: time for a redefinition. Heart 87:121–125PubMedCentralCrossRefPubMed

Tei C, Nishimura RA, Seward JB et al (1997) Noninvasive Doppler derived myocardial performance index: correlation with simultaneous measurements of cardiac catheterization measurements. J Am Soc Echocardiogr 10:169–178CrossRefPubMed

Galiuto L, Ignone G, DeMaria A (1998) Contraction and relaxation velocities of the normal left ventricle using pulsed-wave tissue Doppler echocardiography. Am J Cardiol 81:609–614CrossRefPubMed

Erdogan D, Tayyar S, Uysal BA, Icli A, Karabacak M, Ozaydin M, Dogan A (2012) Effects of allopurinol on coronary microvascular and left ventricular function in patients with idiopathic dilated cardiomyopathy. Can J Cardiol 28(6):721–727. doi:10.1016/j.cjca.2012.04.005CrossRefPubMed

Feig DI (2012) Hyperuricemia and hypertension. Adv Chronic Kidney Dis 19(6):377–385. doi:10.1053/j.ackd.2012.05.009CrossRefPubMed

Sato Y, Yamamoto E, Sawa T et al (2011) High-sensitivity cardiac troponin T in essential hypertension. J Cardiol 58(3):226–231CrossRefPubMed

Hellemons ME, Lambers Heerspink HJ et al (2013) High-sensitivity troponin T predicts worsening of albuminuria in hypertension; results of a nested case-control study with confirmation in diabetes. J Hypertens 31(4):805–812CrossRefPubMed

de Lemos JA, Drazner MH, Omland T et al (2010) Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 304(22):2503–2512CrossRefPubMed

10.

Ohkubo T, Imai Y, Tsuji I et al (1997) Relation between nocturnal decline in blood pressure and mortality, the Ohasama Study. Am J Hypertens 10:1201–1207CrossRefPubMed

11.

Lang RM, Bierig M, Devereux RB et al (2005) Chamber Quantification Writing Group. Recommendations for Chamber Quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463CrossRefPubMed

12.

Schiller NB, Shah PM, Crawford M et al (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2:358–367CrossRefPubMed

13.

Devereux RB (1977) Reichek: echocardiographic determination of left ventricular mass in man, anatomic validation of the method. Circulation 55:613–618CrossRefPubMed

14.

Stergiou GS, Salgami EV (2004) World Health Organization-International Society of Hypertension (WHO-ISH); USA Joint National Committee on Prevention, Detection, Evalutiaon, and Treatment of High Blood Pressure (JNC-7); European Soceity of Hypertension-European Society of Cardiology (ESH-ESC). New European, American and International guidelines for hypertension management: agreement and disagreement. Expert Rev Cardiovasc Ther 2:359–368CrossRefPubMed

15.

Yu CM, Lin H, Yang H et al (2002) Progression of systolic abnormalities in patients with “isolated” diastolic heart failure and diastolic dysfunction. Circulation 105:1195–1201CrossRefPubMed

16.

Aizawa Y, Sakata Y, Mano T et al (2011) Transition from asymptomatic diastolic dysfunction to heart failure with preserved ejection fraction: roles of systolic function and ventricular distensibility. Circ J 75:596–602CrossRefPubMed

17.

Takasaki K, Miyata M, Imamura M et al (2012) Left ventricular dysfunction assessed by cardiac time interval analysis among different geometric patterns in untreated hypertension. Circ J 76:1409–1114CrossRefPubMed

18.

Tei C, Ling L, Hodge D et al (1995) New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function-a study in normalsand dilated cardiomyopathy. J Cardiol 26:357–366PubMed

19.

Tei C (1995) New non-invasive index of combined systolic and diastolic ventricular function. J Cardiol 26:135–136PubMed

20.

Tei C, Dujardin K, Hodge D et al (1996) Doppler index combining systolic and diastolic myocardial performance: clinical value in cardiac amyloidosis. J Am Coll Cardiol 28:658–664CrossRefPubMed

21.

Nearchou N, Tsakiris A, Stathakopoulos D et al (1999) A new Doppler index combining systolic and diastolic myocardial performance. Behavior and significance during hospitalization of patients with acute myocardial infarction. Hellenic J Cardiol 40:486–496

22.

Moller J, Sondergaard E, Poulsen S et al (2001) Serial Doppler echocardiographic assessment of left and right ventricular performance after a first myocardial infarction. J Am Soc Echocardiogr 14:249–255CrossRefPubMed

23.

Bruch C, Schmermund A, Marin D et al (2000) Tei index in patients with mild to moderate congestive heart failure. Eur Heart J 21:1888–1895CrossRefPubMed

24.

Poulsen S, Nielsen J, Andersen H (2000) The influence of heart rate on the Doppler derived myocardial performance index. J Am Soc Echocardiogr 13:379–384CrossRefPubMed

25.

Lengyel M (1998) Effect of chronic amiodarone therapy on left ventricular function in dilated cardiomyopathy studied by the new Doppler-index. Orv Hetil 139:1147–1151PubMed

26.

Nishimura E, Ikeda S, Naito T et al (2009) Evaluation of right-ventricular function by Doppler echocardiography in patients with chronic respiratory failure. J Int Med Res 27:65–73

27.

Reichlin T, Hochholzer W, Bassetti S et al (2009) Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 361:858–867CrossRefPubMed

28.

Høiseth AD, Omland T, Hagve T et al (2012) Determinants of high-sensitivity cardiac troponin T during acute exacerbation of chronic obstructive pulmonary disease: a prospective cohort study. BMC Pulmonary Medicine 12:22PubMedCentralCrossRefPubMed

29.

Setsuta K, Kitahara Y, Arae M et al (2011) Elevated cardiac troponin T predicts adverse outcomes in hypertensive patients. Int Heart J 52:164–169CrossRefPubMed

30.

Camici PG, Crea F (2007) Coronary microvascular dysfunction. N Engl J Med 356:830–840CrossRefPubMed

31.

Fortu˜no MA, Ravassa S, Fortu˜no A et al (2001) Cardiomyocyte apoptotic cell death in arterial hypertension: mechanisms and potential management. Hypertension 38:1406–1412CrossRef

32.

Gur M, Yilmaz R, Demirbag R et al (2008) Relationship between myocardial performance index and aortic distensibility in patients with essential hypertension. Int J Clin Pract 62:138–142CrossRefPubMed

33.

Dujardin KS, Tei C, Yeo TC et al (1998) Prognostic value of a Doppler index combining systolic and diastolic performance in idiopathic-dilated cardiomyopathy. Am J Cardiol 82:1071–1076CrossRefPubMed

34.

Krauser DG, Devereux RB (2006) Ventricular hypertrophy and hypertension: prognostic elements and implications for management. Herz 31:305–316CrossRefPubMed

35.

González A, Fortuño MA, Querejeta R et al (2003) Cardiomyocyte apoptosis in hypertensive cardiomyopathy. Cardiovasc Res 59:549–562CrossRefPubMed

36.

Hickman PE, Potter JM, Aroney C et al (2010) Cardiac troponin may be released by ischemia alone, without necrosis. Clin Chim Acta 411:318–323CrossRefPubMed

37.

Katholi RE, Couri DM (2011) Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications. Int J Hypertens 2011:495349. doi:10.4061/2011/495349PubMedCentralCrossRefPubMed

38.

Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM et al (2003) Losartan Intervention for Endpoint reduction in hypertension Study Investigations. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation 108:684–690CrossRefPubMed

39.

Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP (1990) Prognostic implications of echocardiographically determined LV mass in the Framingham heart study. N Engl J Med 322:1561–1566CrossRefPubMed

Titel: Association between high-sensitivity troponin T, left ventricular hypertrophy, and myocardial performance index
verfasst von: Onur Kaypakli, MD
Mustafa Gür, MD
Mehmet Yavuz Gözükara, MD
Hakan Uçar, MD
Ali Kivrak, MD
Taner Şeker, MD
Durmuş Yildiray Şahin, MD
Zafer Elbasan, MD
Caner Türkoğlu, MD
Murat Çayli, MD
Publikationsdatum: 01.11.2015
Verlag: Springer Medizin
Erschienen in: Herz / Ausgabe 7/2015
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-015-4322-3

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Association between high-sensitivity troponin T, left ventricular hypertrophy, and myocardial performance index

Abstract

Background

Aim

Methods

Results

Conclusion

Neu im Fachgebiet Kardiologie

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Darf man die Behandlung eines Neonazis ablehnen?

Update Kardiologie

Springer Medizin

Abstract

Background

Aim

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2015

Evaluation of right atrial dysfunction in patients with corrected tetralogy of Fallot using 3D speckle-tracking echocardiography

Implantierbare hämodynamische Monitorsysteme

Disappearance of subocclusive ostial stenosis of the left anterior descending artery

Complete disappearance of coronary pathology

Device-Therapie bei chronischer Herzinsuffizienz

Kardiale Kontraktilitätsmodulation

Neu im Fachgebiet Kardiologie

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Darf man die Behandlung eines Neonazis ablehnen?

Update Kardiologie